Janux Therapeutics, Inc. Expected to Post FY2028 Earnings of ($1.45) Per Share (NASDAQ:JANX)

Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) – Wedbush issued their FY2028 earnings per share estimates for shares of Janux Therapeutics in a report issued on Tuesday, February 27th. Wedbush analyst R. Driscoll forecasts that the company will post earnings of ($1.45) per share for the year. Wedbush has a “Outperform” rating and a $53.00 […]

Related Keywords

Immunomodulator Tracir ,William Blair ,Nasdaq ,Janux Therapeutics Company Profile ,Janux Therapeutics Inc ,Vanguard Group Inc ,Janux Therapeutics ,Free Report ,Janux Therapeutic ,Capital Partners ,Vanguard Group ,Get Free Report ,Tumor Activatedt Cell Engager ,Tumor Activated Immunomodulator ,Janux Therapeutics Daily ,